‘Amid the relentless drive to maximise workspace, this thoughtful retrofit provides a replicable, inspiring, light-touch solution – by building upwards,’ said the AJ editorial team. Optoppen-style ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Remember when you watched serene commercials about quaint towns with Western and Colonial buildings? The weather was perfect and the people all looked so friendly. Yes, Santa Fe was that quaint town, ...

I just read what may be the single dumbest politics column ever written, an effort by Cardinal News editor Dwayne Yancey to minimize the blue wave in Tuesday’s elections, based on either a stunning ...

Hello, and welcome to Wave Life Sciences 2025 Research Day. [Operator Instructions] Also, as a reminder, this conference is being recorded today. I will now turn the call over to Kate Rausch, Vice ...

To the editor: A front-page article describes a project potentially beginning within a few months to build a “surf park” (“Big wave machine — by the sea — rolling into El Segundo,” Oct. 25). This will ...

It's been just a few weeks since OpenAI dropped its AI slop (sorry, AI video) app, Sora, and the company is already gearing up for its next major wave of updates. In a new post, OpenAI's head of Sora ...

All creators know that making great content is time-consuming work. Retouching photos or editing video can be an hours-long ordeal that puts a strain on your machine, especially if you're working with ...

This is read by an automated voice. Please report any issues or inconsistencies here. During the next decade in 1907, Henry Huntington built his massive Pacific Light and Power Company plant in north ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Florida's economy is on the cusp ...

After becoming the first group to therapeutically edit human RNA in October 2024, Wave Life Sciences has released more data from its ongoing alpha-1 antitrypsin deficiency (AATD) clinical trial—and ...

Wave Life Sciences (NASDAQ:WVE) lost ~21% in the premarket on Wednesday after the company announced data from a Phase 1b/2a trial for its RNA-editing therapy WVE-006 developed with GSK (NYSE:GSK) for ...